跳至主要内容
临床试验/NCT05469204
NCT05469204
已完成
4 期

Effect of Gender-Affirming Estrogen Therapy on Drug Metabolism, Transport, and Gut Microbiota

University of Washington1 个研究点 分布在 1 个国家目标入组 22 人2022年11月1日

概览

阶段
4 期
干预措施
Midazolam oral solution
疾病 / 适应症
Transgender Persons
发起方
University of Washington
入组人数
22
试验地点
1
主要终点
midazolam AUC ratio (treatment/control)
状态
已完成
最后更新
3个月前

概览

简要总结

This project will evaluate the effect of estrogen treatment on how other medications are processed by the body.

详细描述

Estradiol is prepared as a medication that patients may take to increase hormone levels. Changes in estradiol concentrations in the body may affect how the body processes other medicines. The purpose of this study is to find out how estradiol therapy affects a single tracer dose of approved medicines in the blood (midazolam, digoxin, and acetaminophen) and to confirm estradiol treatment does not affect natural bacterial in the gut.

注册库
clinicaltrials.gov
开始日期
2022年11月1日
结束日期
2025年7月30日
最后更新
3个月前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

责任方
Principal Investigator
主要研究者

Lauren Cirrincione

Assistant Professor

University of Washington

入排标准

入选标准

  • Self-identified trans\* adult 18-55 years of age.
  • Not taking estradiol treatment currently.
  • Planning to start injectable estradiol or estradiol tablets for gender-affirming medical care.

排除标准

  • Unwilling/unable to return for project follow-up visits.
  • Unwilling/unable to provide written informed consent.

研究组 & 干预措施

Healthy transgender adults

Healthy transgender adults will be studied on two separate study days and serve as their own control.

干预措施: Midazolam oral solution

Healthy transgender adults

Healthy transgender adults will be studied on two separate study days and serve as their own control.

干预措施: Digoxin Oral Tablet

Healthy transgender adults

Healthy transgender adults will be studied on two separate study days and serve as their own control.

干预措施: Acetaminophen Oral Tablet

Healthy transgender adults

Healthy transgender adults will be studied on two separate study days and serve as their own control.

干预措施: Midazolam Injectable Solution

结局指标

主要结局

midazolam AUC ratio (treatment/control)

时间窗: 0-6 hours

ratio of the area under of the plasma concentration time curve (AUC) of midazolam in the presence to absence of gender-affirming estradiol treatment.

digoxin renal clearance (treatment/control)

时间窗: 0-48

ratio of digoxin renal clearance in the presence to absence of gender-affirming estradiol treatment.

次要结局

  • midazolam Cmax ratio (treatment/control)(0-6 hours)

研究点 (1)

Loading locations...

相似试验